PharmaFrontiers is a commercialization driven biotechnology company that develops autologous cellular therapies for the treatment of multiple sclerosis, congestive heart failure, and diabetes. The company is focused on autologous cellular therapy applications based on its proprietary stem cell and T-cell vaccination technologies. The company is currently in Phase I/II clinical trials of it's novel therapeutic vaccine TovaxinTM, and is in preclinical development of it's autologous stem cell therapy for the indication of congestive heart failure.

PharmaFrontiers has obtained the exclusive, worldwide license to a technology developed by the U.S. Department of Energy's Argonne National Laboratory. This technology allows a patient to donate blood, a relatively painless and easy procedure, which is then taken to the laboratory and processed to obtain mononuclear cells. The blood is rich in mononuclear cells and a 500 ml draw contains approximately one billion of these cells. The monocytes can be dedifferentiated to pluripotent stem cells in the presence of certain growth factors to yield approximately 10 to 100 million stem cells. The resulting stem cells can be expanded and differentiated into other cell types when cultured in the presence of the appropriate growth factors. During the development of this technology the scientists at Argonne Laboratory were able to turn these monocyte derived stem cells into several different types of cells including nerve cells, liver cells, blood vessel cells, and skin cells.